The Use of Lymphoid Cells Expanded in IL-2 for the Adoptive Immunotherapy of Murine and Human Tumors

  • Steven A. Rosenberg
  • Maury Rosenstein
  • Elizabeth Grimm
  • Michael Lotze
  • Amitabha Mazumder
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)

Abstract

The adoptive immunotherapy of cancer refers to the transfer, to the tumor-bearing host, of immunologically competent cells capable of mediating responses against tumor. Specific adoptive immunotherapy is a theoretically attractive approach to the treatment of tumors although few examples exist of the effective treatment of established syngeneic solid tumors using this modality. Early reports from Delorme and Alexander (1964) claimed that thoracic duct lymphocytes from immunized rats as well as lymphocytes from immunized xenogeneic animals (Alexander et al., 1966) could mediate the regression of solid methylcholanthrene-induced sarcomas. Borberg et al. (1972) treated mice bearing the Meth-A sarcoma with up to 4 × 109 immunized syngeneic lymphocytes and succeeded in causing the regression of established tumors. Using the Meth-A tumor, but an alternative method of immunization, Berendt and North (1980) have demonstrated that the intravenous infusion of sensitized T cells from immune donors could cause complete regression of established tumors growing in a T-deficient host. They also showed that infusion of splenocytes from tumor-bearing donors could inhibit this regression, suggesting that suppressor T cells existed in the tumor-bearing host. Fernandez-Cruz et al. (1980) showed that intravenous infusion of immune lymphocytes was capable of curing rats bearing a subcutaneous tumor, and Smith et al. (1977) showed that immunized peritoneal exudate cells from syngeneic guinea pigs were capable of curing guinea pigs with established line 10 hepatoma.

Keywords

Toxicity Lymphoma Penicillin Sarcoma Streptomycin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander, P., Delorme, E. J., and Hall, J. G., 1966, The effect of lymphoid cells from the lymph of specifically immunized sheep on the growth of primary sarcomata in rats, Lancet 1:1186.CrossRefGoogle Scholar
  2. Berendt, M. J., and North, R. J., 1980, T-cell-mediated suppression of anti-tumor immunity: An explanation for progressive growth of an immunogenic tumor, J. Exp. Med. 151:69.PubMedCrossRefGoogle Scholar
  3. Borberg, H., Oettgen, H. F., Choudry, K., and Beattie, E. J., Jr., 1972, Inhibition of established transplants of chemically induced sarcoma in syngeneic mice by lymphocytes from immunized donors, Int. J. Cancer 10:539.PubMedCrossRefGoogle Scholar
  4. Delorme, E. J., and Alexander, P., 1964, Treatment of primary fibrosarcoma in the rat with immune lymphocytes, Lancet 2:117.PubMedCrossRefGoogle Scholar
  5. Eberlein, T. J., Rosenstein, M., and Rosenberg, S. A., 1982a, Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in IL-2, J. Exp. Med. 156:285.Google Scholar
  6. Eberlein, T. J., Rosenstein, M., Spiess, P. J., and Rosenberg, S. A., 1982b, The generation of long term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma, J. Natl. Cancer Inst. 69:109.Google Scholar
  7. Eberlein, T. J., Rosenstein, M., Spiess, P., Wesley, R., and Rosenberg, S. A., 1982c, Adoptive chemoimmunotherapy of a syngeneic murine lymphoma using long term lymphoid cell lines expanded in T cell growth factor (PP-TCGF), Cell. Immunol. 70:248.CrossRefGoogle Scholar
  8. Fernandez-Cruz, E., Woda, B. A., and Feldman, J. D., 1980, Elimination of syngeneic sarcomas in rats by a subset of T-lymphocytes, J. Exp. Med. 152:823.PubMedCrossRefGoogle Scholar
  9. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A., 1982, The lymphokine activated killer cell phenomenon: Lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes, J. Exp. Med. 155:1823.PubMedCrossRefGoogle Scholar
  10. Grimm, E. A., Ramsey, K. M., Mazumder, A., Wilson, D. J., Djeu, J. Y., and Rosenberg, S. A., 1983a, Lymphokine-activated killer cell phenomenon. II. The precursor phenotype is serologically distinct from peripheral T lymphocytes, memory CTL, and NK cells, J. Exp. Med. 157:884.CrossRefGoogle Scholar
  11. Grimm, E. A., Robb, R. J., Roth, J. A., Neckers, L. M., Lachman, L. B., Wilson, D. J., and Rosenberg, S.A., 1983b, Lymphokine-activated killer cell (LAK) phenomenon. III. Evidence that IL-2 alone is sufficient for direct activation of PBL into LAK, J. Exp. Med. 158:1356–1361.CrossRefGoogle Scholar
  12. Kim, B., Rosenstein, M., and Rosenberg, S. A., 1983, Clonal analysis of the lymphoid cells mediating skin allograft rejection: cloned Ly l+2” proliferative, noncytotoxic long term cell lines mediate graft rejection in vivo, Transplantation 36:525–532.PubMedCrossRefGoogle Scholar
  13. Lotze, M. T., and Rosenberg, S. A., 1981, In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin free T cell growth factor (TCGF) and an analysis of its activity, J. Immunol. 126:2215.PubMedGoogle Scholar
  14. Mazumder, A. M., Grimm, E. A., Zhang, H. Z., and Rosenberg, S. A., 1982, Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins, Cancer Res. 42:913.PubMedGoogle Scholar
  15. Mazumder, A., Grimm, E. A., and Rosenberg, S. A., 1983a, Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin, J. Immunol. 130:958.Google Scholar
  16. Mazumder, A., Eberlein, T. J., Grimm, E. A., Wilson, D. J., Keenan, A. M., Aamodt, R., and Rosenberg, S.A., 1984, Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells, Cancer 53:896–905.PubMedCrossRefGoogle Scholar
  17. Rosenberg, S. A., 1982, Potential use of expanded T-lymphoid cells and T-cell clones for the immunotherapy of cancer, in: Isolation, Characterization and Utilization of T Lymphocyte Clones, Academic Press, New York, p. 451.Google Scholar
  18. Rosenberg, S. A., and Terry, W., 1977, Passive immunotherapy of cancer in animals and man, Adv. Cancer Res. 25:323.PubMedCrossRefGoogle Scholar
  19. Rosenstein, M., and Rosenberg, S.A., 1983, T lymphoid cell clones with lytic and proliferative activity to syngeneic tumor, J. Natl. Cancer Inst, (in press).Google Scholar
  20. Rosenstein, M., Eberlein, T., Kemeny, M. M., Sugarbaker, P. H., and Rosenberg, S. A., 1981, In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor, J. Immunol. 127:566.PubMedGoogle Scholar
  21. Rosenstein, M., Eberlein, T., Schwarz, S., and Rosenberg, S. A., 1983, Simplified techniques for the isolation of alloreactive cell lines and clones with specific cytotoxic or proliferative activity, J. Immunol. Methods 61:183–193.PubMedCrossRefGoogle Scholar
  22. Smith, H. G., Harmel, R. P., Hanna, M. G., Jr., Zwilling, B. S., Zbar, B., and Rapp, H. J., 1977, Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune cells, J. Natl. Cancer Inst. 58:1315.PubMedGoogle Scholar
  23. Strausser, J. L., Mazumder, A., Grimm, E. A., Lotze, M. T., and Rosenberg, S. A., 1981, Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens, J. Immunol. 127:266.PubMedGoogle Scholar
  24. Vanky, F. T., Vose, B. M., Fopp, M., and Klein, E., 1979, Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity, J. Natl. Cancer Inst. 62:1407.PubMedGoogle Scholar
  25. Vose, B. M., Vanky, F., Fopp, M., and Klein, E., 1978, In vitro generation of cytotoxicity against autologous human tumor biopsy cells, Int. J. Cancer 21:588.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Steven A. Rosenberg
    • 1
  • Maury Rosenstein
    • 1
  • Elizabeth Grimm
    • 1
  • Michael Lotze
    • 1
  • Amitabha Mazumder
    • 1
  1. 1.Surgery Branch, Division of Cancer Treatment, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations